JP2015525217A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015525217A5 JP2015525217A5 JP2015516221A JP2015516221A JP2015525217A5 JP 2015525217 A5 JP2015525217 A5 JP 2015525217A5 JP 2015516221 A JP2015516221 A JP 2015516221A JP 2015516221 A JP2015516221 A JP 2015516221A JP 2015525217 A5 JP2015525217 A5 JP 2015525217A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- identity
- fusion polypeptide
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000004927 fusion Effects 0.000 claims 15
- 229920001184 polypeptide Polymers 0.000 claims 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 239000003446 ligand Substances 0.000 claims 12
- 108010002350 Interleukin-2 Proteins 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261657264P | 2012-06-08 | 2012-06-08 | |
| US201261657285P | 2012-06-08 | 2012-06-08 | |
| US201261657378P | 2012-06-08 | 2012-06-08 | |
| US61/657,285 | 2012-06-08 | ||
| US61/657,378 | 2012-06-08 | ||
| US61/657,264 | 2012-06-08 | ||
| US201261723081P | 2012-11-06 | 2012-11-06 | |
| US61/723,081 | 2012-11-06 | ||
| US201361778812P | 2013-03-13 | 2013-03-13 | |
| US201361778575P | 2013-03-13 | 2013-03-13 | |
| US61/778,812 | 2013-03-13 | ||
| US61/778,575 | 2013-03-13 | ||
| PCT/US2013/044556 WO2013184942A1 (en) | 2012-06-08 | 2013-06-06 | Ligands modified by circular permutation as agonists and antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017151506A Division JP6545759B2 (ja) | 2012-06-08 | 2017-08-04 | アゴニストおよびアンタゴニストとしての循環置換により修飾されるリガンド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015525217A JP2015525217A (ja) | 2015-09-03 |
| JP2015525217A5 true JP2015525217A5 (enExample) | 2016-07-21 |
| JP6388408B2 JP6388408B2 (ja) | 2018-09-12 |
Family
ID=49712642
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516221A Active JP6388408B2 (ja) | 2012-06-08 | 2013-06-06 | アゴニストおよびアンタゴニストとしての循環置換により修飾されるリガンド |
| JP2015516220A Expired - Fee Related JP6234446B2 (ja) | 2012-06-08 | 2013-06-06 | ムチンドメインポリペプチドに連結された活性タンパク質を含む融合ポリペプチド |
| JP2015516219A Expired - Fee Related JP6322626B2 (ja) | 2012-06-08 | 2013-06-06 | ムチン−ドメインポリペプチドリンカーを含む融合ポリペプチド |
| JP2017151506A Active JP6545759B2 (ja) | 2012-06-08 | 2017-08-04 | アゴニストおよびアンタゴニストとしての循環置換により修飾されるリガンド |
| JP2019113671A Active JP7048543B2 (ja) | 2012-06-08 | 2019-06-19 | アゴニストおよびアンタゴニストとしての循環置換により修飾されるリガンド |
| JP2021195887A Active JP7350041B2 (ja) | 2012-06-08 | 2021-12-02 | アゴニストおよびアンタゴニストとしての循環置換により修飾されるリガンド |
| JP2023085990A Ceased JP2023109948A (ja) | 2012-06-08 | 2023-05-25 | アゴニストおよびアンタゴニストとしての循環置換により修飾されるリガンド |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516220A Expired - Fee Related JP6234446B2 (ja) | 2012-06-08 | 2013-06-06 | ムチンドメインポリペプチドに連結された活性タンパク質を含む融合ポリペプチド |
| JP2015516219A Expired - Fee Related JP6322626B2 (ja) | 2012-06-08 | 2013-06-06 | ムチン−ドメインポリペプチドリンカーを含む融合ポリペプチド |
| JP2017151506A Active JP6545759B2 (ja) | 2012-06-08 | 2017-08-04 | アゴニストおよびアンタゴニストとしての循環置換により修飾されるリガンド |
| JP2019113671A Active JP7048543B2 (ja) | 2012-06-08 | 2019-06-19 | アゴニストおよびアンタゴニストとしての循環置換により修飾されるリガンド |
| JP2021195887A Active JP7350041B2 (ja) | 2012-06-08 | 2021-12-02 | アゴニストおよびアンタゴニストとしての循環置換により修飾されるリガンド |
| JP2023085990A Ceased JP2023109948A (ja) | 2012-06-08 | 2023-05-25 | アゴニストおよびアンタゴニストとしての循環置換により修飾されるリガンド |
Country Status (20)
| Country | Link |
|---|---|
| US (8) | US9296801B2 (enExample) |
| EP (5) | EP2859015B1 (enExample) |
| JP (7) | JP6388408B2 (enExample) |
| AU (3) | AU2013271541C1 (enExample) |
| CA (3) | CA2869786A1 (enExample) |
| CY (2) | CY1120522T1 (enExample) |
| DK (2) | DK2859015T3 (enExample) |
| ES (4) | ES2842677T3 (enExample) |
| HR (2) | HRP20180914T1 (enExample) |
| HU (2) | HUE037849T2 (enExample) |
| LT (2) | LT3401402T (enExample) |
| ME (1) | ME03079B (enExample) |
| NZ (4) | NZ715099A (enExample) |
| PL (2) | PL3401402T3 (enExample) |
| PT (2) | PT2859015T (enExample) |
| RS (2) | RS61391B1 (enExample) |
| SI (2) | SI2859015T1 (enExample) |
| SM (2) | SMT202100007T1 (enExample) |
| TR (2) | TR201808753T4 (enExample) |
| WO (3) | WO2013184939A2 (enExample) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3401402T (lt) * | 2012-06-08 | 2020-12-28 | Alkermes Pharma Ireland Limited | Ligandai, modifikuoti cirkuliarinės permutacijos pagalba, kaip agonistai ir antagonistai |
| MA40094B1 (fr) * | 2014-08-06 | 2022-05-31 | Univ Miami | Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation |
| AU2015364396B2 (en) * | 2014-12-19 | 2018-08-09 | Alkermes, Inc. | Single chain Fc fusion proteins |
| US11938193B2 (en) | 2016-01-08 | 2024-03-26 | Washington University | Compositions comprising chemerin and methods of use thereof |
| EP3474884A4 (en) | 2016-06-22 | 2020-08-19 | Alkermes, Inc. | COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNOSTIMULANT AND ANTI-INFLAMMATORY PROPERTIES OF IL-10 |
| US11141463B2 (en) | 2016-07-11 | 2021-10-12 | The National Institute for Biotechnology in the Negev Ltd. | Fusion proteins with extended serum half life |
| EP3600429B1 (en) * | 2017-03-20 | 2023-10-25 | Bio-Techne Corporation | Il-37 fusion protein and methods of making and using same |
| KR101784288B1 (ko) * | 2017-04-26 | 2017-10-11 | (주)넥스젠바이오텍 | 피부 세포 증식 효과가 증가한 성장 분화 인자 11과 열 충격 단백질 10의 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선용 화장료 조성물 |
| KR101800200B1 (ko) | 2017-05-26 | 2017-11-23 | (주)넥스젠바이오텍 | 항산화 활성 및 피부 세포 증식 효과가 증가한 성장 분화 인자 11과 상피세포 성장인자의 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선용 화장료 조성물 |
| JP7244089B2 (ja) | 2017-06-27 | 2023-03-22 | コデクシス， インコーポレイテッド | ペニシリンｇアシラーゼ |
| CN107362351B (zh) * | 2017-09-04 | 2020-11-10 | 上海市儿童医院 | Il-36r的拮抗剂在制备镇痛药物中的应用 |
| EP3728302A1 (en) | 2017-12-19 | 2020-10-28 | Xencor, Inc. | Engineered il-2 fc fusion proteins |
| US11267863B2 (en) | 2018-01-19 | 2022-03-08 | Pepgene Inc. | N-terminal fusion partner for producing recombinant polypeptide, and method for producing recombinant polypeptide using same |
| BR112020018709A2 (pt) * | 2018-03-28 | 2021-01-05 | Bristol-Myers Squibb Company | Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso |
| WO2019209078A1 (ko) * | 2018-04-26 | 2019-10-31 | 주식회사 굳티셀 | 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| CN108948178A (zh) * | 2018-07-20 | 2018-12-07 | 安他杰（杭州）生物医药科技有限公司 | 一种改良的人il-37蛋白及其应用 |
| CN109251896A (zh) * | 2018-08-13 | 2019-01-22 | 中山大学 | 一株高表达hKLs-his蛋白的细胞株及其制备方法和应用 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| GB201820547D0 (en) | 2018-12-17 | 2019-01-30 | Oxford Univ Innovation | Modified antibodies |
| US20210038684A1 (en) * | 2019-06-11 | 2021-02-11 | Alkermes Pharma Ireland Limited | Compositions and Methods for Cancer Immunotherapy |
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
| JP7355326B2 (ja) * | 2019-08-05 | 2023-10-03 | デンカ株式会社 | 経粘膜投与薬剤 |
| CA3157229A1 (en) | 2019-10-18 | 2021-04-22 | Alkermes Pharma Ireland Limited | Immunomodulatory il-2 agents in combination with immune checkpoint inhibitors |
| PT4065585T (pt) | 2019-11-25 | 2025-09-30 | Alkermes Inc | Compostos macrocíclicos substituídos e métodos de tratamento relacionados |
| TW202136317A (zh) | 2019-12-20 | 2021-10-01 | 美商再生元醫藥公司 | 新穎之ｉｌ２促效劑及其使用方法（二） |
| WO2021136223A1 (en) * | 2019-12-31 | 2021-07-08 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion proteins of glp-1 and gdf15 and conjugates thereof |
| WO2021150674A1 (en) * | 2020-01-24 | 2021-07-29 | Alkermes, Inc. | Methods of purification |
| US20210292384A1 (en) * | 2020-03-21 | 2021-09-23 | Larix Bioscience Llc | Bispecific and trispecific functional molecules of ACE2 and complement pathways and their use |
| EP4135752A4 (en) * | 2020-04-15 | 2024-06-19 | Alkermes Pharma Ireland Limited | IMMUNOSTIMULATORY AGENTS IN COMBINATION WITH ANGIOGENESIS INHIBITORS |
| AU2021257874A1 (en) * | 2020-04-15 | 2022-11-17 | Mural Oncology, Inc. | Immunostimulatory agents in combination with angiogenesis inhibitors |
| JP2023524639A (ja) | 2020-04-22 | 2023-06-13 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 患者特異的免疫療法用細胞の製造調整システム及び調整方法 |
| CA3176826A1 (en) | 2020-05-04 | 2021-11-11 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| TW202208616A (zh) | 2020-05-04 | 2022-03-01 | 美商艾歐凡斯生物治療公司 | 改良之腫瘤反應性ｔ細胞的選擇 |
| AU2021270745A1 (en) * | 2020-05-11 | 2022-12-15 | Mural Oncology, Inc. | IL-2 fusion polypeptide compositions and methods of making and using the same |
| EP4149514A4 (en) * | 2020-05-11 | 2024-06-26 | Alkermes Pharma Ireland Limited | IL-2 FUSION POLYPEPTIDE COMPOSITIONS AND METHODS OF MAKING AND USING THEM |
| CN111662973B (zh) * | 2020-05-28 | 2023-08-25 | 广州医科大学附属第一医院（广州呼吸中心） | 与慢性阻塞性肺疾病易感性辅助诊断相关的snp位点及其应用 |
| EP4186928A4 (en) * | 2020-07-08 | 2024-10-09 | Nanjing Normal University | Fusion polypeptide and polypeptide dimer, and use thereof |
| CN111826400A (zh) * | 2020-07-21 | 2020-10-27 | 中科宝承生物医学科技有限公司 | 一种双特异性抗体nk细胞制备方法及其细胞和应用 |
| WO2022026358A1 (en) * | 2020-07-27 | 2022-02-03 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Multifunctional immunoglobulin-fold polypeptides from alternative translational initiation and termination |
| WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| US20230372397A1 (en) | 2020-10-06 | 2023-11-23 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| WO2022098954A1 (en) | 2020-11-06 | 2022-05-12 | Nektar Therapeutics | Tlr agonist compounds and related cancer immunotherapy methods |
| WO2022099695A1 (en) * | 2020-11-16 | 2022-05-19 | Jiangsu Cell Tech Medical Research Institute Co., Ltd. | Cd164 fusion and uses thereof |
| MX2023006599A (es) | 2020-12-04 | 2023-06-19 | Visterra Inc | Metodos de uso de agentes de interleucina-2. |
| WO2022125941A1 (en) | 2020-12-11 | 2022-06-16 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors |
| WO2022133149A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocytes |
| WO2022133140A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| TW202242085A (zh) | 2020-12-31 | 2022-11-01 | 美商艾歐凡斯生物治療公司 | 供自動生產腫瘤浸潤淋巴球的裝置和方法 |
| TW202241508A (zh) | 2021-01-29 | 2022-11-01 | 美商艾歐凡斯生物治療公司 | 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法 |
| CA3207359A1 (en) | 2021-02-05 | 2022-08-11 | Cecile Chartier-Courtaud | Adjuvant therapy for cancer |
| WO2022187741A2 (en) | 2021-03-05 | 2022-09-09 | Iovance Biotherapeutics, Inc. | Tumor storage and cell culture compositions |
| US20240191191A1 (en) | 2021-03-19 | 2024-06-13 | Iovance Biotherapeutics, Inc. | Methods for infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils |
| CN117440972A (zh) | 2021-03-24 | 2024-01-23 | 奥克梅斯公司 | Upar抗体和具有所述抗体的融合蛋白 |
| KR20240032711A (ko) | 2021-03-25 | 2024-03-12 | 이오반스 바이오테라퓨틱스, 인크. | T-세포 공배양 효능 검정 및 세포 치료제와 함께 사용하기 위한 방법 및 조성물 |
| KR20230162013A (ko) | 2021-03-26 | 2023-11-28 | 이나뜨 파르마 에스.에이. | Nk 세포 관여를 위해 사이토카인에 융합된 nkp46-결합 부위, 암 항원 결합 부위를 포함하는 다중특이적 단백질 |
| JP2024515189A (ja) | 2021-04-19 | 2024-04-05 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 細胞免疫療法におけるキメラ共刺激受容体、ケモカイン受容体、及びそれらの使用 |
| WO2022245754A1 (en) | 2021-05-17 | 2022-11-24 | Iovance Biotherapeutics, Inc. | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
| CN117616050A (zh) | 2021-06-09 | 2024-02-27 | 先天制药公司 | 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质 |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| TW202317623A (zh) | 2021-06-14 | 2023-05-01 | 美商再生元醫藥公司 | 基於il2之治療劑及其使用方法 |
| CA3226111A1 (en) | 2021-07-22 | 2023-01-26 | Iovance Biotherapeutics, Inc. | Method for cryopreservation of solid tumor fragments |
| EP4377446A1 (en) | 2021-07-28 | 2024-06-05 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
| CN113735980A (zh) * | 2021-08-23 | 2021-12-03 | 中国医学科学院北京协和医院 | 一种自融合串联蛋白修饰方法及其应用 |
| US20240424097A1 (en) | 2021-09-09 | 2024-12-26 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1 talen knockdown |
| JP2024534581A (ja) | 2021-09-24 | 2024-09-20 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球のための拡張プロセス及び薬剤 |
| AR127482A1 (es) | 2021-10-27 | 2024-01-31 | Iovance Biotherapeutics Inc | Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente |
| CA3237410A1 (en) | 2021-11-10 | 2023-05-19 | Friedrich Graf Finck VON FINCKENSTEIN | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
| US20230151095A1 (en) | 2021-11-12 | 2023-05-18 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
| US20250099588A1 (en) | 2022-01-28 | 2025-03-27 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
| CA3243416A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | TUMOR INFILTRATION LYMPHOCYTES MODIFIED TO EXPRESS PAYLOADS |
| CA3247638A1 (en) | 2022-04-06 | 2023-10-12 | Maria Fardis | TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CARCINOMA (NSCLC) WITH TUMOR-INFILTRATING LYMPHOCYTE THERAPIES |
| CA3248034A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT |
| KR102798377B1 (ko) * | 2022-04-26 | 2025-04-22 | 전남대학교산학협력단 | 원형순열에 기반한 기능성 재조합 인간 섬유아세포 성장인자 7의 제조방법 및 그 용도 |
| CA3251533A1 (en) | 2022-05-10 | 2023-11-16 | Iovance Biotherapeutics, Inc. | TREATMENT OF CANCER PATIENTS WITH TUMOR-INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH AN IL-15R AGONIST |
| WO2023235790A1 (en) * | 2022-06-01 | 2023-12-07 | University Of Miami | Bifunctional il-2 and il-10 fusion proteins and uses thereof |
| WO2024011114A1 (en) | 2022-07-06 | 2024-01-11 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
| CN117003852B (zh) * | 2022-07-07 | 2024-11-05 | 北京大学 | 白细胞介素-2的拓扑改造及其作为自身免疫病药物的应用 |
| EP4565683A1 (en) | 2022-08-01 | 2025-06-11 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| EP4583890A1 (en) | 2022-09-09 | 2025-07-16 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
| JP2025531877A (ja) | 2022-09-09 | 2025-09-25 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｐｄ－１／ｔｉｇｉｔ ｔａｌｅｎダブルノックダウンを使用したｔｉｌ製品を生成するためのプロセス |
| CN117106024B (zh) * | 2022-10-21 | 2024-05-24 | 南京市妇幼保健院 | 一种人血清多肽agdmp1及其在改善胰岛素抵抗中的应用 |
| JP2025537155A (ja) | 2022-11-04 | 2025-11-14 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｃｄ３９／ｃｄ１０３選択に関連した腫瘍浸潤リンパ球（ｔｉｌ）拡張のための方法 |
| WO2024102636A1 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and mica/b |
| KR20250122544A (ko) | 2022-11-21 | 2025-08-13 | 이오반스 바이오테라퓨틱스, 인크. | 종양 침윤 림프구의 확장을 위한 2차원 공정 및 이를 통한 요법 |
| WO2024118836A1 (en) | 2022-11-30 | 2024-06-06 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes with shortened rep step |
| EP4431525A1 (en) | 2023-03-16 | 2024-09-18 | Anaveon AG | Il-2 fusion protein |
| WO2024133825A1 (en) * | 2022-12-22 | 2024-06-27 | Anaveon AG | Anti-pd-1 antibody antigen-binding domain and immunoconjugate |
| JP2025531047A (ja) * | 2023-02-21 | 2025-09-19 | レメゲン シーオー．，エルティーディー． | 癌用のｉｌ－１５アゴニスト |
| WO2025015318A2 (en) | 2023-07-13 | 2025-01-16 | Iovance Biotherapeutics, Inc. | Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes |
| AU2024292473A1 (en) | 2023-07-19 | 2026-01-29 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc |
| AU2023455215A1 (en) * | 2023-07-25 | 2026-02-05 | Zahav Bioscience Llc | Cytokine compositions and methods of use thereof |
| WO2025054540A1 (en) | 2023-09-08 | 2025-03-13 | Iovance Biotherapeutics, Inc. | Methods of gene-editing using programmable nucleases |
| US20250243279A1 (en) | 2023-10-17 | 2025-07-31 | Xencor, Inc. | Bispecific antibodies that bind to nkp46 and mica/b |
| WO2025101484A1 (en) | 2023-11-06 | 2025-05-15 | Iovance Biotherapeutics, Inc. | Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies |
| WO2025171182A1 (en) | 2024-02-08 | 2025-08-14 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine |
| WO2026006784A1 (en) | 2024-06-28 | 2026-01-02 | Iovance Biotherapeutics, Inc. | Methods of making tumor reactive peripheral blood lymphocytes (trpbl) |
| WO2026035866A1 (en) | 2024-08-07 | 2026-02-12 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3992518A (en) | 1974-10-24 | 1976-11-16 | G. D. Searle & Co. | Method for making a microsealed delivery device |
| US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
| IE60901B1 (en) | 1986-08-21 | 1994-08-24 | Vestar Inc | Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics |
| US5872095A (en) | 1990-05-01 | 1999-02-16 | Chiron Corporation | IL-1 receptor antagonists medicaments |
| US5840496A (en) | 1990-10-09 | 1998-11-24 | Chiron Corporation | Method for diagnosing endometrial cancer |
| US5635599A (en) * | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
| IT1270662B (it) | 1994-10-13 | 1997-05-07 | Applied Research Systems | Antagonista della interleuchina-1 |
| US5837495A (en) | 1994-10-13 | 1998-11-17 | Applied Research Systems Ars Holding N.V. | DNA encoding interleukin-1 antagonist |
| US5660848A (en) | 1994-11-02 | 1997-08-26 | The Population Council, Center For Biomedical Research | Subdermally implantable device |
| US6518061B1 (en) | 1995-03-15 | 2003-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
| US5614191A (en) | 1995-03-15 | 1997-03-25 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
| US6096728A (en) | 1996-02-09 | 2000-08-01 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| PT929293E (pt) | 1996-08-23 | 2004-03-31 | Sequus Pharm Inc | Lipossomas contendo um composto de cisplatina |
| JP2001503396A (ja) | 1996-10-11 | 2001-03-13 | アルザ コーポレイション | 治療用リポソーム組成物および方法 |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| US5969105A (en) | 1996-10-25 | 1999-10-19 | Feng; Yiqing | Stem cell factor receptor agonists |
| JP2001503266A (ja) | 1996-10-25 | 2001-03-13 | ジー．ディー．サール アンド カンパニー | 環状に並べ替えたエリスロポイエチン受容体アゴニスト |
| US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| JP2002526380A (ja) | 1997-10-31 | 2002-08-20 | バイオミラ，インコーポレイテッド | 癌関連ｍｕｃ−１ムチン誘発免疫抑制の治療におけるｍｕｃ−１誘導体とその使用法 |
| US6562347B1 (en) * | 1998-03-12 | 2003-05-13 | The United States Of America As Represented By The Department Of Health And Human Services | Chemokine-tumor antigen fusion proteins as cancer vaccines |
| AU3380099A (en) * | 1998-04-03 | 1999-10-25 | University Of Washington | Circularly permuted biotin binding proteins |
| US6715485B1 (en) | 1999-03-03 | 2004-04-06 | Optinose As | Nasal delivery device |
| US6808902B1 (en) * | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| CA2391080A1 (en) * | 1999-11-12 | 2001-05-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Erythropoietin forms with improved properties |
| US7544477B2 (en) | 2000-01-13 | 2009-06-09 | Kalobios, Inc. | Circularly permutated, interaction-activated proteins |
| US6497870B1 (en) | 2000-05-22 | 2002-12-24 | Hyseq, Inc. | Therapeutic uses of il-1 receptor antagonist |
| EP1290170A2 (en) | 2000-06-16 | 2003-03-12 | Asterion Limited | Binding agents: chimeric ligand/receptor proteins |
| ES2262680T3 (es) | 2000-09-14 | 2006-12-01 | Ares Trading S.A. | Uso de una quimera il-6r/il-6 en la enfermedad de huntington. |
| UA93662C2 (uk) * | 2000-12-07 | 2011-03-10 | Эли Лилли Энд Компани | Гетерологічний пептидильований глюкагон-подібний білок та його застосування для виготовлення лікарського засобу для лікування пацієнтів, що страждають на ожиріння або інсулінонезалежний цукровий діабет |
| EP1357934A1 (en) | 2001-02-06 | 2003-11-05 | MERCK PATENT GmbH | Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity |
| JP4421894B2 (ja) | 2001-07-20 | 2010-02-24 | アブソーバー アクチボラゲット | 血液型抗原融合ポリペプチドおよびその使用方法 |
| US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| IL147412A0 (en) | 2001-12-31 | 2002-08-14 | Yeda Res & Dev | The use of il6r/il6 chimera in nerve cell regeneration |
| US7416730B2 (en) * | 2002-04-18 | 2008-08-26 | Yeda Research And Development Co. Ltd. | Derivatives of the IL-2 receptor gamma chain, their production and use |
| ATE551069T1 (de) * | 2002-04-22 | 2012-04-15 | Recopharma Ab | Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung |
| US20080241166A1 (en) | 2002-06-28 | 2008-10-02 | Domantis Limited | Ligands that bind a receptor |
| WO2004015057A2 (en) | 2002-08-09 | 2004-02-19 | Recopharma Ab | Mucin-immunoglobulin fusion proteins |
| US20040175359A1 (en) | 2002-11-12 | 2004-09-09 | Desjarlais John Rudolph | Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity |
| MXPA05007019A (es) * | 2002-12-30 | 2005-08-18 | Amgen Inc | Terapia de combinacion con factores co-estimuladores. |
| GB0315182D0 (en) | 2003-06-28 | 2003-08-06 | Asterion Ltd | Cytokine variant polypeptides |
| WO2005034863A2 (en) * | 2003-10-03 | 2005-04-21 | Jarikuma Corporation | Countermeasures against malaria |
| US8129506B2 (en) | 2003-10-24 | 2012-03-06 | Genzyme Corporation | Modulation of the interaction of MUC1 with MUC1 ligands |
| US8454963B2 (en) * | 2003-11-13 | 2013-06-04 | Musc Foundation For Research Development | Tissue targeted complement modulators |
| US7576183B2 (en) * | 2003-12-24 | 2009-08-18 | Los Alamos National Security, Llc | Structure-based receptor MIMICS targeted against bacterial superantigen toxins |
| WO2005072392A2 (en) | 2004-01-28 | 2005-08-11 | John Hopkins University | Methods for making and using molecular switches involving circular permutation |
| PT1729810T (pt) | 2004-04-02 | 2018-11-22 | Swedish Orphan Biovitrum Ab Publ | Métodos de redução da agregação de il-ira |
| US7700318B2 (en) | 2004-08-25 | 2010-04-20 | Amprotein Corporation | Chimeric polypeptide and use thereof |
| JP2008521489A (ja) * | 2004-11-24 | 2008-06-26 | テラカイン コーポレイション | 眼球内薬物送達のための移植物 |
| WO2006086607A2 (en) | 2005-02-10 | 2006-08-17 | Emory University | Novel proteins with enhanced functionality and methods of making novel proteins using circular permutation |
| CN101309932B (zh) * | 2005-08-12 | 2012-04-11 | 独立行政法人理化学研究所 | 新粘蛋白型糖蛋白及其应用 |
| EP1777294A1 (en) * | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| JPWO2007063907A1 (ja) * | 2005-11-30 | 2009-05-07 | 塩野義製薬株式会社 | ペプチド糖鎖付加体およびそれを有効成分とする医薬 |
| DE602005015733D1 (de) * | 2005-12-02 | 2009-09-10 | Apceth Gmbh & Co Kg | Chemokin-Mucin Fusionsproteine mit einer GPI-Ankerdomäne und deren Verwendung als Tumor-Immun-Adjuvanzien oder in der Geweberegeneration |
| GB0606946D0 (en) | 2006-04-06 | 2006-05-17 | Asterion Ltd | Polypeptide antagonist |
| US20100063258A1 (en) | 2006-06-28 | 2010-03-11 | The Board Of Trustees Of The Leland Stanford Junior University | Fusion protein constructs |
| JP5492563B2 (ja) | 2006-12-12 | 2014-05-14 | バイオレクシス ファーマシューティカル コーポレーション | トランスフェリン融合タンパク質ライブラリー |
| US7816324B2 (en) | 2007-03-13 | 2010-10-19 | Board Of Regents, The University Of Texas System | Composition and method for the treatment of diseases affected by a peptide receptor |
| US20080286211A1 (en) * | 2007-04-27 | 2008-11-20 | Barker Nicholas P | Using mucin glycoproteins in combination with therapeutic agents to treat epithelial lesions and disorders of impaired mucin function |
| AU2008269032B2 (en) * | 2007-06-27 | 2013-12-05 | Novartis Ag | Complexes of IL-15 and IL-15Ralpha and uses thereof |
| CN103298935A (zh) * | 2007-08-15 | 2013-09-11 | 阿穆尼克斯公司 | 用于改善生物活性多肽性能的组合物和方法 |
| DE102007049830A1 (de) | 2007-10-16 | 2009-04-23 | Henkel Ag & Co. Kgaa | Neue Proteinvarianten durch zirkulare Permutation |
| EP2050759A1 (en) | 2007-10-19 | 2009-04-22 | CONARIS research institute AG | Soluble gp 130 muteins with improved binding activity |
| US9687559B2 (en) | 2008-03-19 | 2017-06-27 | The Board Of Regents Of The University Of Oklahoma | Heparosan polymers and methods of making and using same for the enhancement of therapeutics |
| CA2726128C (en) * | 2008-05-29 | 2016-10-18 | The Board Of Trustees Of The Leland Stanford Junior University | Cell line, system and method for optical control of secondary messengers |
| JP5604297B2 (ja) * | 2008-06-17 | 2014-10-08 | 株式会社糖鎖工学研究所 | 糖鎖付加ｇｌｐ−１ペプチド |
| GB0815216D0 (en) | 2008-08-21 | 2008-09-24 | Asterion Ltd | Interleukin |
| SI2393828T1 (sl) * | 2009-02-03 | 2017-01-31 | Amunix Operating Inc. | Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo |
| EP3028707A1 (en) * | 2009-05-01 | 2016-06-08 | Ophthotech Corporation | Methods for treating or preventing ophthalmological diseases |
| WO2011103049A2 (en) * | 2010-02-16 | 2011-08-25 | Immune Disease Institute, Inc. | Method for screening receptors/ligands interactions |
| US8734774B2 (en) | 2010-04-02 | 2014-05-27 | University Of Rochester | Protease activated cytokines |
| US9119869B2 (en) | 2010-04-29 | 2015-09-01 | Ronald J. Shebuski | Mucin derived polypeptides |
| CN107337735B (zh) * | 2010-07-29 | 2021-06-22 | 巴扎德制药公司 | 嵌合il-1受体i型激动剂和拮抗剂 |
| EP3851459B1 (en) * | 2010-09-21 | 2024-05-01 | Altor BioScience, LLC | Multimeric il-15 soluble fusion molecules and methods of making and using same |
| US9511151B2 (en) * | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| US9745359B2 (en) * | 2012-05-18 | 2017-08-29 | Adda Biotech Inc. | Protein and protein conjugate for diabetes treatment, and applications thereof |
| LT3401402T (lt) | 2012-06-08 | 2020-12-28 | Alkermes Pharma Ireland Limited | Ligandai, modifikuoti cirkuliarinės permutacijos pagalba, kaip agonistai ir antagonistai |
-
2013
- 2013-06-06 LT LTEP18162555.9T patent/LT3401402T/lt unknown
- 2013-06-06 EP EP13801437.8A patent/EP2859015B1/en active Active
- 2013-06-06 WO PCT/US2013/044552 patent/WO2013184939A2/en not_active Ceased
- 2013-06-06 TR TR2018/08753T patent/TR201808753T4/tr unknown
- 2013-06-06 NZ NZ715099A patent/NZ715099A/en unknown
- 2013-06-06 TR TR2018/09046T patent/TR201809046T4/tr unknown
- 2013-06-06 HR HRP20180914TT patent/HRP20180914T1/hr unknown
- 2013-06-06 LT LTEP13801437.8T patent/LT2859015T/lt unknown
- 2013-06-06 ES ES18162555T patent/ES2842677T3/es active Active
- 2013-06-06 NZ NZ630849A patent/NZ630849A/en unknown
- 2013-06-06 JP JP2015516221A patent/JP6388408B2/ja active Active
- 2013-06-06 US US13/911,834 patent/US9296801B2/en active Active
- 2013-06-06 AU AU2013271541A patent/AU2013271541C1/en not_active Ceased
- 2013-06-06 DK DK13801437.8T patent/DK2859015T3/en active
- 2013-06-06 ES ES13800676.2T patent/ES2675784T3/es active Active
- 2013-06-06 HU HUE13801437A patent/HUE037849T2/hu unknown
- 2013-06-06 SI SI201331030T patent/SI2859015T1/sl unknown
- 2013-06-06 CA CA2869786A patent/CA2869786A1/en not_active Abandoned
- 2013-06-06 EP EP13799943.9A patent/EP2874639B1/en active Active
- 2013-06-06 SI SI201331831T patent/SI3401402T1/sl unknown
- 2013-06-06 DK DK18162555.9T patent/DK3401402T3/da active
- 2013-06-06 PL PL18162555T patent/PL3401402T3/pl unknown
- 2013-06-06 PL PL13801437T patent/PL2859015T3/pl unknown
- 2013-06-06 PT PT138014378T patent/PT2859015T/pt unknown
- 2013-06-06 US US13/911,818 patent/US9156897B2/en active Active
- 2013-06-06 EP EP18162555.9A patent/EP3401402B1/en active Active
- 2013-06-06 SM SM20210007T patent/SMT202100007T1/it unknown
- 2013-06-06 CA CA2869787A patent/CA2869787C/en active Active
- 2013-06-06 PT PT181625559T patent/PT3401402T/pt unknown
- 2013-06-06 ES ES13799943.9T patent/ES2667558T3/es active Active
- 2013-06-06 SM SM20180363T patent/SMT201800363T1/it unknown
- 2013-06-06 HU HUE18162555A patent/HUE052908T2/hu unknown
- 2013-06-06 ES ES13801437.8T patent/ES2675568T3/es active Active
- 2013-06-06 EP EP13800676.2A patent/EP2858672B1/en active Active
- 2013-06-06 NZ NZ630851A patent/NZ630851A/en not_active IP Right Cessation
- 2013-06-06 NZ NZ630848A patent/NZ630848A/en not_active IP Right Cessation
- 2013-06-06 WO PCT/US2013/044551 patent/WO2013184938A2/en not_active Ceased
- 2013-06-06 EP EP20201402.3A patent/EP3825405A1/en not_active Withdrawn
- 2013-06-06 WO PCT/US2013/044556 patent/WO2013184942A1/en not_active Ceased
- 2013-06-06 RS RS20210004A patent/RS61391B1/sr unknown
- 2013-06-06 JP JP2015516220A patent/JP6234446B2/ja not_active Expired - Fee Related
- 2013-06-06 ME MEP-2018-155A patent/ME03079B/me unknown
- 2013-06-06 CA CA2869674A patent/CA2869674A1/en not_active Abandoned
- 2013-06-06 AU AU2013271542A patent/AU2013271542B2/en not_active Ceased
- 2013-06-06 JP JP2015516219A patent/JP6322626B2/ja not_active Expired - Fee Related
- 2013-06-06 RS RS20180664A patent/RS57369B1/sr unknown
- 2013-06-06 US US13/911,827 patent/US9359415B2/en active Active
- 2013-06-06 AU AU2013271545A patent/AU2013271545C1/en active Active
-
2014
- 2014-02-18 US US14/182,536 patent/US9428563B2/en active Active
-
2015
- 2015-09-01 US US14/841,809 patent/US10023623B2/en active Active
-
2016
- 2016-02-16 US US15/044,310 patent/US10183979B2/en active Active
- 2016-07-25 US US15/218,193 patent/US10407481B2/en active Active
-
2017
- 2017-08-04 JP JP2017151506A patent/JP6545759B2/ja active Active
-
2018
- 2018-06-20 CY CY20181100640T patent/CY1120522T1/el unknown
-
2019
- 2019-06-19 JP JP2019113671A patent/JP7048543B2/ja active Active
- 2019-07-23 US US16/519,231 patent/US20200040053A1/en not_active Abandoned
-
2020
- 2020-12-09 HR HRP20201973TT patent/HRP20201973T1/hr unknown
-
2021
- 2021-01-07 CY CY20211100009T patent/CY1124525T1/el unknown
- 2021-12-02 JP JP2021195887A patent/JP7350041B2/ja active Active
-
2023
- 2023-05-25 JP JP2023085990A patent/JP2023109948A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015525217A5 (enExample) | ||
| JP2015524403A5 (enExample) | ||
| JP2013172734A5 (enExample) | ||
| ES2545895T3 (es) | Proteína de fusión anticancerígena | |
| JP2015212284A5 (enExample) | ||
| EA201291362A1 (ru) | Слитый белок против злокачественных новообразований | |
| RU2016146198A (ru) | Терапевтические dll4-связывающие белки | |
| JP2015134796A5 (enExample) | ||
| JP2019515650A5 (enExample) | ||
| HRP20190799T1 (hr) | Imunocitokini na bazi il-15 i sushi domene il-15r alfa | |
| HRP20150108T1 (hr) | Peptidna cjepiva za rak koji eksprimira tumoru pridružene antigene | |
| NZ627111A (en) | Variants of activin iib receptor polypeptides and uses thereof | |
| JP2014193892A5 (enExample) | ||
| JP2014224126A5 (enExample) | ||
| JP2013527765A5 (enExample) | ||
| JP2010519176A5 (enExample) | ||
| MX2021000030A (es) | Metodos y composiciones que utilizan polipeptidos variantes klotho. | |
| JP2014525439A5 (enExample) | ||
| EA036805B8 (ru) | Белок cd24 для подавления ответа хозяина на damp | |
| JP2015504052A5 (enExample) | ||
| MX2015007421A (es) | Proteinas de tipo espiral enrollada modificadas que tienen propiedades mejoradas. | |
| HK1215441A1 (zh) | 人血清白蛋白结合化合物及其融合蛋白 | |
| NZ629309A (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
| EP2589658A4 (en) | PARTIAL REGION POLYPEPTIDE OF REIC / DKK-3 PROTEIN | |
| JP2016508143A5 (enExample) |